XPO1-dependent nuclear export as a target for cancer therapy

Nancy G. Azizian, Nancy G. Azizian, Yulin Li, Yulin Li

Research output: Contribution to journalReview articlepeer-review

115 Scopus citations


Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.

Original languageEnglish (US)
Article number61
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - Jun 1 2020


  • CRM1
  • Cancer
  • Nuclear export
  • Selective inhibitor of nuclear export (SINE)
  • Selinexor
  • XPO1

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research


Dive into the research topics of 'XPO1-dependent nuclear export as a target for cancer therapy'. Together they form a unique fingerprint.

Cite this